Amarin Q1 total revenue up 7% to $45.1M; operating loss narrows 32%; cash flow positive

AMARIN CORP PLCUK

2026-Q1 EPS reported -$0.03 revenue$45,132,000

Total net revenue $45.1M (+7% YoY); U.S. product revenue $35.6M flat; European revenue $4.9M (-9%); ROW $2.8M.
Operating loss narrowed to $11.3M from $16.8M; net loss $10.5M ($0.03 EPS) vs $15.7M ($0.04 EPS).
Cash and investments $307.8M; debt-free; second consecutive quarter of positive cash flow.
Reaffirms full-year 2026 positive cash flow; targeting ~$70M cost savings; restructuring charges $39.6M cumulative.
Recordati launched VAZKEPA in 10 European countries; U.S. VAZCEPA branded Rx up 17% YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMARIN CORP PLCUK reported the three months ended March 31, 2026 results: revenue $45.1 million, net income $(10.5) million. Guidance reaffirmed.

Period: the three months ended March 31, 2026
Revenue: $45.1 million
Net income: $(10.5) million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On April 29, 2026, Amarin Corporation plc (“ Amarin ”) issued a press release announcing its financial results for the three months ended March 31, 2026

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

AMARIN CORP PLCUK filing history →

Source: SEC EDGAR

accession 0001193125-26-188935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.